Suki has raised $90M in series E funding, betting that the next fight in clinical AI is everything that happens after the note is written.
Healthier Capital led the round, with Zoom Ventures, Philips Ventures and Hercules Capital joining. The company expects $60M to $80M in revenue this year.
Suki’s voice assistant now runs inside more than 450 healthcare organizations, and roughly 30 health-tech partners license the technology. That is a wide footprint for a startup that started as a dictation tool.
From listening to acting
The company says the new capital goes toward agentic features that handle post-visit chores such as referrals and scheduling. Those tasks are where clinicians lose hours after the patient leaves.
It is a crowded lane. Rivals including Abridge, Ambience and Microsoft’s Nuance have all moved beyond transcription into workflow automation.
Why investors are still writing cheques
Ambient documentation remains one of the few AI categories with clear, measurable payoff for health systems. Suki’s pitch rests on owning the clinical conversation and then acting on it.
The company last drew attention in August, when it unbundled voice notes for Epic and MEDITECH hospitals. The series E extends that enterprise push rather than opening a new chapter.
Whether scribes can become agents – reliably, and inside regulated clinical workflows – is the question the next year of deployments will answer.
